Shots:
- Eli Lilly has entered into a licensing agreement with Alchemab for ATLX-1282 to treat ALS & other neurodegenerative conditions
- As per the deal, Alchemab will receive ~$415M, incl. an upfront payment, potential discovery, development, & commercial payments, as well as royalties, plus will handle early P-I trial activities, with Lilly leading further development & commercialization
- Deal builds on a Jan 2025 agreement in which Alchemab & Lilly partnered to discover, develop, & market up to 5 ALS therapies, with Alchemab receiving an undisclosed upfront payment & being eligible for discovery, development & commercial milestone payments, plus royalties
Ref: PRNewswire | Image: Eli Lilly and Alchemab Therapeutics
Related News:- Eli Lilly Partners with Creyon Bio for Accelerated Discovery and Development of RNA-Targeted Oligonucleotides for Various Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
